Back to News
Market Impact: 0.2
Raymond James Initiates Coverage of Camp4 Therapeutics with Strong Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Fintel reports that Raymond James initiated coverage of Camp4 Therapeutics (NASDAQGM:CAMP) on October 23, 2026, with a Strong Buy recommendation. The excerpt provides no price target or market reaction and then switches to a description of CalAmp Corp., so the company details in that description are not attributed to Camp4.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
CAMP0.60
More News
- Top restaurant stocks to watch, according to Raymond James
- Citizens reiterates Spotify stock rating on product momentum
- T-Mobile stock hits 52-week low at 147.89 USD
- Next week brings major risks for the stock market, just as the AI trade keeps faltering
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- SpaceX bear flips to big bull because of AI business. Analyst now sees 70% gain